ARCHIVES

DCCR Merit Review Of Contracts Finds Most Perform Satisfactorily; 21 Phased Out Early

This article is from The Cancer Letter archive.

Vol. 05 No. 01 | January 5, 1979

Download PDF Visit The Full Archive

Related Articles

Sanofi: Zaltrap Price Reflects Competing Drugs In Second-Line Metastatic Colon Cancer

November 1, 2012

Tobacco Industry Walkout Unlikely To Imperil Legislation

April 17, 1998

ACCC To Consider Cancer Act Changes HSA Problems

January 7, 1977

Four More COP Awards Announced

January 9, 1981

Gregory Reaman Named Associate Director of FDA Office of Oncology Drug Products

June 3, 2011

NCI Marmoset Colony Available For Research

February 11, 1983